Tübingen

CureVac sues BioNTech, claiming Covid-19 vaccine infringes key mRNA patents

Messenger RNA vaccine biotech CureVac is suing BioNTech, alleging that its rival’s Covid-19 vaccine infringes on intellectual property built on more than two decades of research. BioNTech responded that its work is original and the company will defend against the infringement allegations.

By Frank Vinluan

BioPharma, Policy

CureVac denies reports that Trump admin sought to acquire Covid-19 vaccine rights

German media reported Sunday that the administration had sought to lure its scientists to the U.S. Another company, Moderna, said Monday that it had dosed the first participant in its Phase I vaccine trial.

By Alaric DeArment

CureVac sues BioNTech, claiming Covid-19 vaccine infringes key mRNA patents

CureVac denies reports that Trump admin sought to acquire Covid-19 vaccine rights

Transforming Patient Care: The Role of AI-Powered Assistants